Axon Enterprise (NASDAQ:AXON) Price Target Raised to $600.00 at Needham & Company LLC

Axon Enterprise (NASDAQ:AXON) had its target price hoisted by equities researchers at Needham & Company LLC from $525.00 to $600.00 in a report released on Friday,Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock. Needham & Company LLC’s target price indicates a potential downside of 0.53% from the company’s current price.

Other equities research analysts have also issued reports about the company. Jefferies Financial Group began coverage on Axon Enterprise in a research report on Wednesday, July 17th. They issued a “buy” rating and a $385.00 price target for the company. Craig Hallum increased their price target on Axon Enterprise from $370.00 to $376.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. The Goldman Sachs Group increased their price target on Axon Enterprise from $385.00 to $441.00 and gave the company a “buy” rating in a research report on Wednesday, October 23rd. JMP Securities increased their price target on Axon Enterprise from $430.00 to $500.00 and gave the company a “market outperform” rating in a research report on Thursday, October 31st. Finally, Bank of America began coverage on Axon Enterprise in a research report on Wednesday, July 17th. They issued a “buy” rating and a $380.00 price target for the company. Two analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, Axon Enterprise presently has a consensus rating of “Moderate Buy” and an average target price of $412.42.

Axon Enterprise Price Performance

Shares of AXON opened at $603.18 on Friday. Axon Enterprise has a 12-month low of $212.88 and a 12-month high of $611.88. The business’s fifty day moving average is $414.16 and its 200 day moving average is $347.27. The company has a quick ratio of 2.52, a current ratio of 2.88 and a debt-to-equity ratio of 0.35. The stock has a market cap of $45.58 billion, a P/E ratio of 155.86, a P/E/G ratio of 11.70 and a beta of 0.94.

Insider Activity

In other news, Director Caitlin Elizabeth Kalinowski sold 450 shares of the stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $373.03, for a total transaction of $167,863.50. Following the completion of the transaction, the director now owns 7,379 shares in the company, valued at approximately $2,752,588.37. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CFO Brittany Bagley sold 4,338 shares of the stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $378.95, for a total transaction of $1,643,885.10. Following the completion of the transaction, the chief financial officer now owns 98,825 shares in the company, valued at approximately $37,449,733.75. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Caitlin Elizabeth Kalinowski sold 450 shares of the stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $373.03, for a total value of $167,863.50. Following the transaction, the director now owns 7,379 shares of the company’s stock, valued at $2,752,588.37. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 369,172 shares of company stock valued at $136,270,842 in the last ninety days. 6.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Avantax Advisory Services Inc. boosted its position in shares of Axon Enterprise by 0.8% during the 1st quarter. Avantax Advisory Services Inc. now owns 5,302 shares of the biotechnology company’s stock valued at $1,659,000 after acquiring an additional 40 shares during the last quarter. Foundations Investment Advisors LLC bought a new stake in shares of Axon Enterprise during the 3rd quarter valued at about $221,000. Sequoia Financial Advisors LLC boosted its position in shares of Axon Enterprise by 4.9% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 1,727 shares of the biotechnology company’s stock valued at $690,000 after acquiring an additional 81 shares during the last quarter. Zurich Insurance Group Ltd FI boosted its position in shares of Axon Enterprise by 1.9% during the 2nd quarter. Zurich Insurance Group Ltd FI now owns 205,015 shares of the biotechnology company’s stock valued at $60,324,000 after acquiring an additional 3,832 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC raised its holdings in shares of Axon Enterprise by 21.7% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 9,153 shares of the biotechnology company’s stock valued at $2,693,000 after buying an additional 1,634 shares in the last quarter. Institutional investors own 79.08% of the company’s stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.